A RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER PHASE III STUDY OF PENPULIMAB (AK105) COMBINED WITH CHEMOTHERAPY VERSUS PLACEBO COMBINED WITH CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA

Registry ID

AK105-304

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

AKESO BIOPHARMA CO., LTD

Start date

2023-08-11

Last update

2023-01-04

Conditions

• NASOPHARYNGEAL CARCINOMA

Related clinical trials

• A PHASE 2 STUDY USING CHEMOIMMUNOTHERAPY WITH GEMCITABINE, CISPLATIN AND NIVOLUMAB IN NEWLY DIAGNOSES NASOPHARYNGEAL CARCINOMA (NPC)
• TRANSPARENT: A SINGLE-ARM STUDY OF TORIPALIMAB IN COMBINATION WITH CISPLATIN AND GEMCITABINE IN RECURRENT METASTATIC NASOPHARYNGEAL CARCINOMA SYSTEMIC TREATMENT NAÏVE PARTICIPANTS
• RANDOMIZED PHASE II AND PHASE III STUDIES OF INDIVIDUALIZED TREATMENT FOR NASOPHARYNGEAL CARCINOMA BASED ON BIOMARKER EPSTEIN BARR VIRUS (EBV) DEOXYRIBONUCLEIC ACID

View on source registry